PALATIN TECHNOLOGIES INC (PTN)
US6960775020 - Common Stock
We assign a fundamental rating of 2 out of 10 to PTN. PTN was compared to 587 industry peers in the Biotechnology industry. Both the profitability and financial health of PTN have multiple concerns. PTN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PTN had negative earnings in the past year.
PTN had a negative operating cash flow in the past year.
PTN had negative earnings in 4 of the past 5 years.
In the past 5 years PTN reported 4 times negative operating cash flow.
1.2 Ratios
PTN's Return On Assets of -233.08% is on the low side compared to the rest of the industry. PTN is outperformed by 91.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -233.08% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-101.35%
ROA(5y)-59.25%
ROE(3y)-9276.56%
ROE(5y)-5564.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 95.39%, PTN belongs to the best of the industry, outperforming 96.59% of the companies in the same industry.
PTN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PTN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PTN has been increased compared to 1 year ago.
The number of shares outstanding for PTN has been increased compared to 5 years ago.
PTN has a worse debt/assets ratio than last year.
2.2 Solvency
PTN has an Altman-Z score of -49.99. This is a bad value and indicates that PTN is not financially healthy and even has some risk of bankruptcy.
PTN has a worse Altman-Z score (-49.99) than 93.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -49.99 |
ROIC/WACCN/A
WACC9.12%
2.3 Liquidity
A Current Ratio of 1.09 indicates that PTN should not have too much problems paying its short term obligations.
PTN's Current ratio of 1.09 is on the low side compared to the rest of the industry. PTN is outperformed by 87.20% of its industry peers.
A Quick Ratio of 1.09 indicates that PTN should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.09, PTN is doing worse than 86.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
PTN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.23%, which is quite good.
The Revenue has grown by 145.82% in the past year. This is a very strong growth!
Measured over the past years, PTN shows a very negative growth in Revenue. The Revenue has been decreasing by -40.88% on average per year.
EPS 1Y (TTM)16.23%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-330.77%
Revenue 1Y (TTM)145.82%
Revenue growth 3Y243.18%
Revenue growth 5Y-40.88%
Revenue growth Q2Q97.49%
3.2 Future
The Earnings Per Share is expected to grow by 25.25% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 102.59% on average over the next years. This is a very strong growth
EPS Next Y15.1%
EPS Next 2Y27.15%
EPS Next 3Y30.4%
EPS Next 5Y25.25%
Revenue Next Year-3.81%
Revenue Next 2Y29.42%
Revenue Next 3Y112.86%
Revenue Next 5Y102.59%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
PTN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PTN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PTN's earnings are expected to grow with 30.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.15%
EPS Next 3Y30.4%
5. Dividend
5.1 Amount
No dividends for PTN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PALATIN TECHNOLOGIES INC
NYSEARCA:PTN (5/3/2024, 7:13:58 PM)
After market: 2 -0.11 (-5.21%)2.11
+0.06 (+2.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap34.06M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -233.08% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.39% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.09 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)16.23%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y15.1%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)145.82%
Revenue growth 3Y243.18%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y